{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T03:27:52Z","timestamp":1788492472835,"version":"build-2803163510"},"reference-count":131,"publisher":"Bioscientifica","issue":"8","license":[{"start":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T00:00:00Z","timestamp":1772236800000},"content-version":"vor","delay-in-days":211,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["K12CA086913, CA262279, CA231978"],"award-info":[{"award-number":["K12CA086913, CA262279, CA231978"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Systems biology approaches have been applied to prostate cancer to model how individual cellular and molecular components interact to influence cancer development, progression, and treatment responses. The integration of multi-omic experimental data with computational models has provided insights into the molecular characteristics of prostate cancer and emerging treatment strategies that have the potential to improve patient outcomes. Here, we highlight recent advancements that have emerged from systems modeling in prostate cancer. These include descriptions of the molecular landscape of prostate cancer and how genomic alterations inform computational models of disease progression, how evolutionary processes give rise to mechanisms of therapeutic resistance, and the development of innovative treatment strategies such as adaptive therapy. We also highlight current challenges in prostate cancer that can be addressed through systems biology approaches. These include tumor heterogeneity, poor immunotherapy response, a paucity of experimental model systems, and the ongoing translation of computational models for clinical decision making. Leveraging systems biology approaches has the potential to lead to a better understanding of the disease and better patient outcomes in the treatment of prostate cancer.<\/jats:p>","DOI":"10.1530\/erc-25-0067","type":"journal-article","created":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T13:08:33Z","timestamp":1754312913000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-8","source":"Crossref","is-referenced-by-count":3,"title":["Systems biology successes and areas for opportunity in prostate cancer"],"prefix":"10.1530","volume":"32","author":[{"given":"Michael V","family":"Orman","sequence":"first","affiliation":[{"name":"University of Colorado Anschutz Medical Campus, Department of Pharmacology 1 , , ,","place":["Aurora, Colorado, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura S","family":"Graham","sequence":"additional","affiliation":[{"name":"University of Colorado Anschutz Medical Campus, Department of Medical Oncology 2 , , ,","place":["Aurora, Colorado, USA"]},{"name":"University of Colorado Anschutz Medical Campus, University of Colorado Comprehensive Cancer Center 3 , , ,","place":["Aurora, Colorado, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D","family":"Cramer","sequence":"additional","affiliation":[{"name":"University of Colorado Anschutz Medical Campus, Department of Pharmacology 1 , , ,","place":["Aurora, Colorado, USA"]},{"name":"University of Colorado Anschutz Medical Campus, University of Colorado Comprehensive Cancer Center 3 , , ,","place":["Aurora, Colorado, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3158-9682","authenticated-orcid":true,"given":"James C","family":"Costello","sequence":"additional","affiliation":[{"name":"University of Colorado Anschutz Medical Campus, Department of Pharmacology 1 , , ,","place":["Aurora, Colorado, USA"]},{"name":"University of Colorado Anschutz Medical Campus, University of Colorado Comprehensive Cancer Center 3 , , ,","place":["Aurora, Colorado, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2025,8,4]]},"reference":[{"key":"2026070905455657600_bib1","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/carcin\/bgp261","article-title":"Cancer systems biology: a network modeling perspective","volume":"31","author":"Kreeger","year":"2010","journal-title":"Carcinogenesis"},{"key":"2026070905455657600_bib2","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/nrclinonc.2014.6","article-title":"Cancer systems biology: a peek into the future of patient care?","volume":"11","author":"Werner","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"key":"2026070905455657600_bib3","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1038\/onc.2014.291","article-title":"Cancer systems biology: embracing complexity to develop better anticancer therapeutic strategies","volume":"34","author":"Du","year":"2015","journal-title":"Oncogene"},{"key":"2026070905455657600_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev-bioeng-103122-030552","article-title":"Systems biology of the cancer cell","volume":"27","author":"Janes","year":"2025","journal-title":"Annu Rev Biomed Eng"},{"key":"2026070905455657600_bib5","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/s41580-023-00615-w","article-title":"The technological landscape and applications of single-cell multi-omics","volume":"24","author":"Baysoy","year":"2023","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2026070905455657600_bib6","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1016\/j.molcel.2022.05.022","article-title":"Unbiased spatial proteomics with single-cell resolution in tissues","volume":"82","author":"Mund","year":"2022","journal-title":"Mol Cell"},{"key":"2026070905455657600_bib7","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1158\/0008-5472.CAN-16-1467","article-title":"Novel hybrid phenotype revealed in small cell lung cancer by a transcription factor network model that can explain tumor heterogeneity","volume":"77","author":"Udyavar","year":"2017","journal-title":"Cancer Res"},{"key":"2026070905455657600_bib8","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1038\/s41467-017-01968-5","article-title":"Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer","volume":"8","author":"Zhang","year":"2017","journal-title":"Nat Commun"},{"key":"2026070905455657600_bib9","doi-asserted-by":"crossref","first-page":"4675","DOI":"10.1158\/0008-5472.CAN-15-1337","article-title":"Application of evolutionary principles to cancer therapy","volume":"75","author":"Enriquez-Navas","year":"2015","journal-title":"Cancer Res"},{"key":"2026070905455657600_bib10","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.72626","article-title":"Patient-specific Boolean models of signalling networks guide personalised treatments","volume":"11","author":"Montagud","year":"2022","journal-title":"Elife"},{"key":"2026070905455657600_bib11","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3390\/cells8030201","article-title":"Complex systems biology approach in connecting PI3K-Akt and NF-\u03baB pathways in prostate cancer","volume":"8","author":"Shankar","year":"2019","journal-title":"Cells"},{"key":"2026070905455657600_bib12","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.3390\/app10082721","article-title":"Review: mathematical modeling of prostate cancer and clinical application","volume":"10","author":"Phan","year":"2020","journal-title":"Appl Sci"},{"key":"2026070905455657600_bib13","doi-asserted-by":"crossref","DOI":"10.1098\/rsif.2019.0195","article-title":"Mechanistic modelling of prostate-specific antigen dynamics shows potential for personalized prediction of radiation therapy outcome","volume":"16","author":"Lorenzo","year":"2019","journal-title":"J R Soc Interface"},{"key":"2026070905455657600_bib14","article-title":"Prediction of treatment efficacy for prostate cancer using a mathematical model","volume":"6","author":"Peng","year":"2016","journal-title":"Sci Rep"},{"key":"2026070905455657600_bib15","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1002\/ijc.33588","article-title":"Cancer statistics for the year 2020: an overview","volume":"149","author":"Ferlay","year":"2021","journal-title":"Int J Cancer"},{"key":"2026070905455657600_bib16","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/nature11125","article-title":"The mutational landscape of lethal castration-resistant prostate cancer","volume":"487","author":"Grasso","year":"2012","journal-title":"Nature"},{"key":"2026070905455657600_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00029","article-title":"Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making","volume":"2017","author":"Abida","year":"2017","journal-title":"JCO Precis Oncol"},{"key":"2026070905455657600_bib18","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/s41588-018-0078-z","article-title":"The long tail of oncogenic drivers in prostate cancer","volume":"50","author":"Armenia","year":"2018","journal-title":"Nat Genet"},{"key":"2026070905455657600_bib19","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.cell.2015.06.053","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"162","author":"Robinson","year":"2015","journal-title":"Cell"},{"key":"2026070905455657600_bib20","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/ng.2279","article-title":"Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer","volume":"44","author":"Barbieri","year":"2012","journal-title":"Nat Genet"},{"key":"2026070905455657600_bib21","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.cell.2013.03.021","article-title":"Punctuated evolution of prostate cancer genomes","volume":"153","author":"Baca","year":"2013","journal-title":"Cell"},{"key":"2026070905455657600_bib22","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/nature20788","article-title":"Genomic hallmarks of localized, non-indolent prostate cancer","volume":"541","author":"Fraser","year":"2017","journal-title":"Nature"},{"key":"2026070905455657600_bib23","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1158\/1078-0432.CCR-21-2577","article-title":"Differences in prostate cancer genomes by self-reported race: contributions of genetic ancestry, modifiable cancer risk factors, and clinical factors","volume":"28","author":"Stopsack","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2026070905455657600_bib24","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41597-023-02335-4","article-title":"A harmonized resource of integrated prostate cancer clinical, -omic, and signature features","volume":"10","author":"Laajala","year":"2023","journal-title":"Sci Data"},{"key":"2026070905455657600_bib25","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ccr.2010.05.026","article-title":"Integrative genomic profiling of human prostate cancer","volume":"18","author":"Taylor","year":"2010","journal-title":"Cancer Cell"},{"key":"2026070905455657600_bib26","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.cell.2015.10.025","article-title":"The molecular taxonomy of primary prostate cancer","volume":"163","author":"Abeshouse","year":"2015","journal-title":"Cell"},{"key":"2026070905455657600_bib27","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/s41391-019-0167-9","article-title":"Decipher identifies men with otherwise clinically favorable-intermediate risk disease who may not be good candidates for active surveillance","volume":"23","author":"Herlemann","year":"2020","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2026070905455657600_bib28","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1186\/1471-2164-14-690","article-title":"Analytical validation of the oncotype DX prostate cancer assay \u2013 a clinical RT-PCR assay optimized for prostate needle biopsies","volume":"14","author":"Knezevic","year":"2013","journal-title":"BMC Genom"},{"key":"2026070905455657600_bib29","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/bju.14452","article-title":"NICE advice \u2013 prolaris gene expression assay for assessing long-term risk of prostate cancer progression: \u00a9 NICE (2016) prolaris gene expression assay for assessing long-term risk of prostate cancer progression","volume":"122","author":"NICE","year":"2018","journal-title":"BJU Int"},{"key":"2026070905455657600_bib30","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1126\/science.1117679","article-title":"Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer","volume":"310","author":"Tomlins","year":"2005","journal-title":"Science"},{"key":"2026070905455657600_bib31","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1002\/pros.21265","article-title":"TMPRSS2-ERG gene fusion prevalence and class are significantly different in prostate cancer of Caucasian, African-American and Japanese patients","volume":"71","author":"Magi-Galluzzi","year":"2011","journal-title":"Prostate"},{"key":"2026070905455657600_bib32","doi-asserted-by":"crossref","first-page":"11139","DOI":"10.1073\/pnas.1411446111","article-title":"Copy number alteration burden predicts prostate cancer relapse","volume":"111","author":"Hieronymus","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026070905455657600_bib33","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1360352","article-title":"ProstaMine: a bioinformatics tool for identifying subtype-specific co-alterations associated with aggressiveness in prostate cancer","volume":"15","author":"Orman","year":"2024","journal-title":"Front Pharmacol"},{"key":"2026070905455657600_bib34","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.cell.2018.03.029","article-title":"The evolutionary landscape of localized prostate cancers drives clinical aggression","volume":"173","author":"Espiritu","year":"2018","journal-title":"Cell"},{"key":"2026070905455657600_bib35","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1128\/MCB.22.5.1495-1503.2002","article-title":"Conditional loss of Nkx3.1 in adult mice induces prostatic intraepithelial neoplasia","volume":"22","author":"Abdulkadir","year":"2002","journal-title":"Mol Cell Biol"},{"key":"2026070905455657600_bib36","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1158\/0008-5472.CAN-11-2724","article-title":"Suppression of Tak1 promotes prostate tumorigenesis","volume":"72","author":"Wu","year":"2012","journal-title":"Cancer Res"},{"key":"2026070905455657600_bib37","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1158\/1541-7786.MCR-20-0913","article-title":"MAP3K7 loss drives enhanced androgen signaling and independently confers risk of recurrence in prostate cancer with joint loss of CHD1","volume":"19","author":"Jillson","year":"2021","journal-title":"Mol Cancer Res"},{"key":"2026070905455657600_bib38","first-page":"4997","article-title":"Frequent inactivation of PTEN\/MMAC1 in primary prostate cancer","volume":"57","author":"Cairns","year":"1997","journal-title":"Cancer Res"},{"key":"2026070905455657600_bib39","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S1535-6108(03)00215-0","article-title":"Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer","volume":"4","author":"Wang","year":"2003","journal-title":"Cancer Cell"},{"key":"2026070905455657600_bib40","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.ccell.2019.04.012","article-title":"CHD1 loss alters AR binding at lineage-specific enhancers and modulates distinct transcriptional programs to drive prostate tumorigenesis","volume":"35","author":"Augello","year":"2019","journal-title":"Cancer Cell"},{"key":"2026070905455657600_bib41","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.09207","article-title":"SPOP mutation leads to genomic instability in prostate cancer","volume":"4","author":"Boysen","year":"2015","journal-title":"Elife"},{"key":"2026070905455657600_bib42","article-title":"Platelet transfusion thresholds among children admitted to a pediatric intensive care unit","volume":"9","author":"Alsheikh","year":"2017","journal-title":"Cureus"},{"key":"2026070905455657600_bib43","doi-asserted-by":"crossref","first-page":"11428","DOI":"10.1073\/pnas.1902651116","article-title":"Genomic correlates of clinical outcome in advanced prostate cancer","volume":"116","author":"Abida","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026070905455657600_bib44","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11912-020-01003-9","article-title":"Clinical and biological features of neuroendocrine prostate cancer","volume":"23","author":"Yamada","year":"2021","journal-title":"Curr Oncol Rep"},{"key":"2026070905455657600_bib45","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1158\/1078-0432.CCR-13-3309","article-title":"Aggressive variants of castration-resistant prostate cancer","volume":"20","author":"Beltran","year":"2014","journal-title":"Clin Cancer Res"},{"key":"2026070905455657600_bib46","doi-asserted-by":"crossref","first-page":"4492","DOI":"10.1172\/JCI128212","article-title":"Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer","volume":"129","author":"Labrecque","year":"2019","journal-title":"J Clin Investig"},{"key":"2026070905455657600_bib47","first-page":"3886","article-title":"Nkx3.1; pten mutant mice develop invasive prostate adenocarcinoma and lymph node metastases","volume":"63","author":"Abate-Shen","year":"2003","journal-title":"Cancer Res"},{"key":"2026070905455657600_bib48","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1158\/0008-5472.CAN-18-4110","article-title":"Loss of PTEN accelerates NKX3.1 degradation to promote prostate cancer progression","volume":"79","author":"Bowen","year":"2019","journal-title":"Cancer Res"},{"key":"2026070905455657600_bib49","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1126\/science.aah4199","article-title":"Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance","volume":"355","author":"Ku","year":"2017","journal-title":"Science"},{"key":"2026070905455657600_bib50","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/1235","article-title":"Pten is essential for embryonic development and tumour suppression","volume":"19","author":"Di Cristofano","year":"1998","journal-title":"Nat Genet"},{"key":"2026070905455657600_bib51","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/ng.370","article-title":"Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate","volume":"41","author":"Carver","year":"2009","journal-title":"Nat Genet"},{"key":"2026070905455657600_bib52","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1158\/0008-5472.CAN-14-1596","article-title":"Coordinate loss of MAP3K7 and CHD1 promotes aggressive prostate cancer","volume":"75","author":"Rodrigues","year":"2015","journal-title":"Cancer Res"},{"key":"2026070905455657600_bib53","doi-asserted-by":"crossref","first-page":"D955","DOI":"10.1093\/nar\/gks1111","article-title":"Genomics of drug sensitivity in cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells","volume":"41","author":"Yang","year":"2013","journal-title":"Nucleic Acids Res"},{"key":"2026070905455657600_bib54","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0069008","article-title":"Boolean network model for cancer pathways: predicting carcinogenesis and targeted therapy outcomes","volume":"8","author":"Fumi\u00e3","year":"2013","journal-title":"PLoS One"},{"key":"2026070905455657600_bib55","doi-asserted-by":"crossref","first-page":"4353","DOI":"10.1038\/s41467-018-06867-x","article-title":"Mutational interactions define novel cancer subgroups","volume":"9","author":"Kuipers","year":"2018","journal-title":"Nat Commun"},{"key":"2026070905455657600_bib56","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1158\/0008-5472.CAN-22-1910","article-title":"Bayesian machine learning enables identification of transcriptional network disruptions associated with drug-resistant prostate cancer","volume":"83","author":"Blatti","year":"2023","journal-title":"Cancer Res"},{"key":"2026070905455657600_bib57","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1186\/s13059-014-0439-6","article-title":"Unraveling the clonal hierarchy of somatic genomic aberrations","volume":"15","author":"Prandi","year":"2014","journal-title":"Genome Biol"},{"key":"2026070905455657600_bib58","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/s41588-018-0086-z","article-title":"Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets","volume":"50","author":"Wedge","year":"2018","journal-title":"Nat Genet"},{"key":"2026070905455657600_bib59","article-title":"Genomic evolution shapes prostate cancer disease type","volume":"4","author":"Woodcock","year":"2024","journal-title":"Cell Genom"},{"key":"2026070905455657600_bib60","doi-asserted-by":"crossref","DOI":"10.1172\/JCI147878","article-title":"Tumor subtype defines distinct pathways of molecular and clinical progression in primary prostate cancer","volume":"131","author":"Liu","year":"2021","journal-title":"J Clin Investig"},{"key":"2026070905455657600_bib61","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1056\/NEJMoa1212299","article-title":"Intermittent versus continuous androgen deprivation in prostate cancer","volume":"368","author":"Hussain","year":"2013","journal-title":"N Engl J Med"},{"key":"2026070905455657600_bib62","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1056\/NEJMoa2303974","article-title":"Improved outcomes with enzalutamide in biochemically recurrent prostate cancer","volume":"389","author":"Freedland","year":"2023","journal-title":"N Engl J Med"},{"key":"2026070905455657600_bib63","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMoa1201546","article-title":"Intermittent androgen suppression for rising PSA level after radiotherapy","volume":"367","author":"Crook","year":"2012","journal-title":"N Engl J Med"},{"key":"2026070905455657600_bib64","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1001\/jamaoncol.2018.3395","article-title":"Optimizing cancer treatment using game theory: a review","volume":"5","author":"Stankov\u00e1","year":"2018","journal-title":"JAMA Oncol"},{"key":"2026070905455657600_bib65","doi-asserted-by":"crossref","first-page":"4894","DOI":"10.1158\/0008-5472.CAN-08-3658","article-title":"Adaptive therapy","volume":"69","author":"Gatenby","year":"2009","journal-title":"Cancer Res"},{"key":"2026070905455657600_bib66","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1038\/s41467-020-15424-4","article-title":"Prostate-specific antigen dynamics predict individual responses to intermittent androgen deprivation","volume":"11","author":"Brady-Nicholls","year":"2020","journal-title":"Nat Commun"},{"key":"2026070905455657600_bib67","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.76284","article-title":"Evolution-based mathematical models significantly prolong response to abiraterone in metastatic castrate-resistant prostate cancer and identify strategies to further improve outcomes","volume":"11","author":"Zhang","year":"2022","journal-title":"Elife"},{"key":"2026070905455657600_bib68","doi-asserted-by":"crossref","first-page":"4413","DOI":"10.1158\/1078-0432.CCR-19-0006","article-title":"Multidrug cancer therapy in metastatic castrate-resistant prostate cancer: an evolution-based strategy","volume":"25","author":"West","year":"2019","journal-title":"Clin Cancer Res"},{"key":"2026070905455657600_bib69","doi-asserted-by":"crossref","first-page":"5225","DOI":"10.3390\/cancers14215225","article-title":"A phase 1b adaptive androgen deprivation therapy trial in metastatic castration sensitive prostate cancer","volume":"14","author":"Zhang","year":"2022","journal-title":"Cancers"},{"key":"2026070905455657600_bib70","first-page":"15","article-title":"Budget impact of adaptive abiraterone therapy for castration-resistant prostate cancer","volume":"14","author":"Mason","year":"2021","journal-title":"Am Health Drug Benefits"},{"key":"2026070905455657600_bib71","doi-asserted-by":"crossref","first-page":"7499","DOI":"10.1158\/0008-5472.CAN-09-1354","article-title":"Lessons from applied ecology: cancer control using an evolutionary double bind","volume":"69","author":"Gatenby","year":"2009","journal-title":"Cancer Res"},{"key":"2026070905455657600_bib72","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/459508a","article-title":"A change of strategy in the war on cancer","volume":"459","author":"Gatenby","year":"2009","journal-title":"Nature"},{"key":"2026070905455657600_bib73","doi-asserted-by":"crossref","first-page":"S48","DOI":"10.1016\/S0720-048X(12)70018-9","article-title":"A unifying theory of carcinogenesis, and why targeted therapy doesn\u2019t work","volume":"81","author":"Gillies","year":"2012","journal-title":"Eur J Radiol"},{"key":"2026070905455657600_bib74","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1158\/0008-5472.CAN-19-2669","article-title":"Towards multidrug adaptive therapy","volume":"80","author":"West","year":"2020","journal-title":"Cancer Res"},{"key":"2026070905455657600_bib75","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/s43856-022-00110-x","article-title":"Spatial structure impacts adaptive therapy by shaping intra-tumoral competition","volume":"2","author":"Strobl","year":"2022","journal-title":"Commun Med"},{"key":"2026070905455657600_bib76","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1038\/s41559-020-1157-y","article-title":"Stromal reactivity differentially drives tumour cell evolution and prostate cancer progression","volume":"4","author":"Frankenstein","year":"2020","journal-title":"Nat Ecol Evol"},{"key":"2026070905455657600_bib77","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.coisb.2019.09.003","article-title":"Modeling genetic heterogeneity of drug response and resistance in cancer","volume":"17","author":"Laajala","year":"2019","journal-title":"Curr Opin Syst Biol"},{"key":"2026070905455657600_bib78","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aad7842","article-title":"Exploiting evolutionary principles to prolong tumor control in preclinical models of breast cancer","volume":"8","author":"Enriquez-Navas","year":"2016","journal-title":"Sci Transl Med"},{"key":"2026070905455657600_bib79","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/nature13121","article-title":"Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma","volume":"508","author":"Sun","year":"2014","journal-title":"Nature"},{"key":"2026070905455657600_bib80","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/nature11814","article-title":"Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance","volume":"494","author":"Das Thakur","year":"2013","journal-title":"Nature"},{"key":"2026070905455657600_bib81","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ebiom.2019.09.023","article-title":"Leveraging transcriptional dynamics to improve BRAF inhibitor responses in melanoma","volume":"48","author":"Smalley","year":"2019","journal-title":"EBioMedicine"},{"key":"2026070905455657600_bib82","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3390\/cancers16020257","article-title":"Testing adaptive therapy protocols using gemcitabine and capecitabine in a preclinical model of endocrine-resistant breast cancer","volume":"16","author":"Seyedi","year":"2024","journal-title":"Cancers"},{"key":"2026070905455657600_bib83","doi-asserted-by":"crossref","first-page":"6362","DOI":"10.1158\/0008-5472.CAN-12-2235","article-title":"Evolutionary approaches to prolong progression-free survival in breast cancer","volume":"72","author":"Silva","year":"2012","journal-title":"Cancer Res"},{"key":"2026070905455657600_bib84","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1038\/s41467-017-01516-1","article-title":"Spatial competition constrains resistance to targeted cancer therapy","volume":"8","author":"Bacevic","year":"2017","journal-title":"Nat Commun"},{"key":"2026070905455657600_bib85","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2024-091262","article-title":"Study protocol for Adaptive ChemoTherapy for Ovarian cancer (ACTOv): a multicentre phase II randomised controlled trial to evaluate the efficacy of adaptive therapy (AT) with carboplatin, based on changes in CA125, in patients with relapsed platinum-sensitive high-grade serous or high-grade endometrioid ovarian cancer","volume":"14","author":"Mukherjee","year":"2024","journal-title":"BMJ Open"},{"key":"2026070905455657600_bib86","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1002\/1097-0142(19921101)70:9<2313::AID-CNCR2820700917>3.0.CO;2-T","article-title":"Multiple cancers in the prostate. Morphologic features of clinically recognized versus incidental tumors","volume":"70","author":"Villers","year":"1992","journal-title":"Cancer"},{"key":"2026070905455657600_bib87","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1038\/ng.3315","article-title":"Spatial genomic heterogeneity within localized, multifocal prostate cancer","volume":"47","author":"Boutros","year":"2015","journal-title":"Nat Genet"},{"key":"2026070905455657600_bib88","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41586-022-04975-9","article-title":"Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer","volume":"608","author":"Herberts","year":"2022","journal-title":"Nature"},{"key":"2026070905455657600_bib89","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/nature10762","article-title":"Clonal evolution in cancer","volume":"481","author":"Greaves","year":"2012","journal-title":"Nature"},{"key":"2026070905455657600_bib90","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000541881","article-title":"The immune microenvironment in prostate cancer: a comprehensive review","volume":"103","author":"Novysedlak","year":"2024","journal-title":"Oncology"},{"key":"2026070905455657600_bib91","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.3389\/fimmu.2020.01218","article-title":"Pan-cancer analysis of immune cell infiltration identifies a prognostic immune-cell characteristic score (ICCS) in lung adenocarcinoma","volume":"11","author":"Zuo","year":"2020","journal-title":"Front Immunol"},{"key":"2026070905455657600_bib92","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.celrep.2016.12.019","article-title":"Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade","volume":"18","author":"Charoentong","year":"2017","journal-title":"Cell Rep"},{"key":"2026070905455657600_bib93","first-page":"210","article-title":"Prostate cancer immunotherapy: a review of recent advancements with novel treatment methods and efficacy","volume":"10","author":"Wang","year":"2022","journal-title":"Am J Clin Exp Urol"},{"key":"2026070905455657600_bib94","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0233260","article-title":"Mismatch repair deficiency in metastatic prostate cancer: response to PD-1 blockade and standard therapies","volume":"15","author":"Graham","year":"2020","journal-title":"PLoS One"},{"key":"2026070905455657600_bib95","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1158\/0008-5472.CAN-08-2654","article-title":"Coordination of intratumoral immune reaction and human colorectal cancer recurrence","volume":"69","author":"Camus","year":"2009","journal-title":"Cancer Res"},{"key":"2026070905455657600_bib96","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.3747\/co.27.5223","article-title":"A review of cancer immunotherapy: from the past, to the present, to the future","volume":"27","author":"Esfahani","year":"2020","journal-title":"Curr Oncol"},{"key":"2026070905455657600_bib97","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nrc3245","article-title":"The immune contexture in human tumours: impact on clinical outcome","volume":"12","author":"Fridman","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"2026070905455657600_bib98","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","article-title":"Approaches to treat immune hot, altered and cold tumours with combination immunotherapies","volume":"18","author":"Galon","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"2026070905455657600_bib99","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1344272","article-title":"Overcoming cold tumors: a combination strategy of immune checkpoint inhibitors","volume":"15","author":"Ouyang","year":"2024","journal-title":"Front Immunol"},{"key":"2026070905455657600_bib100","doi-asserted-by":"crossref","first-page":"5365","DOI":"10.7150\/thno.58390","article-title":"Turning cold tumors into hot tumors by improving T-cell infiltration","volume":"11","author":"Liu","year":"2021","journal-title":"Theranostics"},{"key":"2026070905455657600_bib101","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102227","article-title":"Turning tumors from cold to inflamed to improve immunotherapy response","volume":"101","author":"Gerard","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"2026070905455657600_bib102","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/s41391-021-00340-5","article-title":"How to turn up the heat on the cold immune microenvironment of metastatic prostate cancer","volume":"24","author":"Stultz","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2026070905455657600_bib103","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: synthetic lethality in the clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science"},{"key":"2026070905455657600_bib104","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/nature11005","article-title":"Systematic identification of genomic markers of drug sensitivity in cancer cells","volume":"483","author":"Garnett","year":"2012","journal-title":"Nature"},{"key":"2026070905455657600_bib105","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/nature11003","article-title":"The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity","volume":"483","author":"Barretina","year":"2012","journal-title":"Nature"},{"key":"2026070905455657600_bib106","article-title":"How clinically relevant are prostate cancer cell lines? A comprehensive characterisation and multiomics comparison","author":"Ahmed","year":"2024","journal-title":"bioRxiv"},{"key":"2026070905455657600_bib107","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.cell.2014.08.016","article-title":"Organoid cultures derived from patients with advanced prostate cancer","volume":"159","author":"Gao","year":"2014","journal-title":"Cell"},{"key":"2026070905455657600_bib108","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/nprot.2016.006","article-title":"Organoid culture systems for prostate epithelial and cancer tissue","volume":"11","author":"Drost","year":"2016","journal-title":"Nat Protoc"},{"key":"2026070905455657600_bib109","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1038\/s41467-018-04495-z","article-title":"Patient derived organoids to model rare prostate cancer phenotypes","volume":"9","author":"Puca","year":"2018","journal-title":"Nat Commun"},{"key":"2026070905455657600_bib110","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s12943-021-01426-3","article-title":"Patient derived organoids in prostate cancer: improving therapeutic efficacy in precision medicine","volume":"20","author":"Pamarthy","year":"2021","journal-title":"Mol Cancer"},{"key":"2026070905455657600_bib111","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1038\/s41467-021-21300-6","article-title":"Patient-derived xenografts and organoids model therapy response in prostate cancer","volume":"12","author":"Karkampouna","year":"2021","journal-title":"Nat Commun"},{"key":"2026070905455657600_bib112","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1002\/path.5698","article-title":"Prostate cancer patient-derived organoids: detailed outcome from a prospective cohort of 81 clinical specimens","volume":"254","author":"Servant","year":"2021","journal-title":"J Pathol"},{"key":"2026070905455657600_bib113","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1038\/labinvest.3700310","article-title":"Use of tissue recombination to predict phenotypes of transgenic mouse models of prostate carcinoma","volume":"85","author":"Ishii","year":"2005","journal-title":"Lab Invest"},{"key":"2026070905455657600_bib114","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1210\/en.2004-1123","article-title":"A system for studying epithelial-stromal interactions reveals distinct inductive abilities of stromal cells from benign prostatic hyperplasia and prostate cancer","volume":"146","author":"Barclay","year":"2005","journal-title":"Endocrinology"},{"key":"2026070905455657600_bib115","doi-asserted-by":"crossref","DOI":"10.1101\/pdb.top069880","article-title":"Tissue recombination models for the study of epithelial cancer","volume":"2015","author":"Zong","year":"2015","journal-title":"Cold Spring Harb Protoc"},{"key":"2026070905455657600_bib116","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1095\/biolreprod22.1.19","article-title":"Stromal-epithelial interactions in sex differentiation","volume":"22","author":"Cunha","year":"1980","journal-title":"Biol Reprod"},{"key":"2026070905455657600_bib117","doi-asserted-by":"crossref","first-page":"5678","DOI":"10.1158\/1078-0432.CCR-04-2421","article-title":"Breast cancer molecular subtypes respond differently to preoperative chemotherapy","volume":"11","author":"Rouzier","year":"2005","journal-title":"Clin Cancer Res"},{"key":"2026070905455657600_bib118","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/j.breast.2015.07.008","article-title":"Clinical implications of the intrinsic molecular subtypes of breast cancer","volume":"24","author":"Prat","year":"2015","journal-title":"Breast"},{"key":"2026070905455657600_bib119","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/35021093","article-title":"Molecular portraits of human breast tumours","volume":"406","author":"Perou","year":"2000","journal-title":"Nature"},{"key":"2026070905455657600_bib120","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.ccell.2021.04.014","article-title":"Conserved pan-cancer microenvironment subtypes predict response to immunotherapy","volume":"39","author":"Bagaev","year":"2021","journal-title":"Cancer Cell"},{"key":"2026070905455657600_bib121","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s12929-022-00879-y","article-title":"Spatial multi-omics analyses of the tumor immune microenvironment","volume":"29","author":"Hsieh","year":"2022","journal-title":"J Biomed Sci"},{"key":"2026070905455657600_bib122","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114392","article-title":"Single-cell spatial multiomics reveals tumor microenvironment vulnerabilities in cancer resistance to immunotherapy","volume":"43","author":"Quek","year":"2024","journal-title":"Cell Rep"},{"key":"2026070905455657600_bib123","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003890","article-title":"Spatial transcriptomics of macrophage infiltration in non-small cell lung cancer reveals determinants of sensitivity and resistance to anti-PD1\/PD-L1 antibodies","volume":"10","author":"Larroquette","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2026070905455657600_bib124","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1038\/s41401-023-01079-6","article-title":"Predictive biomarkers of immunotherapy response with pharmacological applications in solid tumors","volume":"44","author":"Kov\u00e1cs","year":"2023","journal-title":"Acta Pharmacol Sin"},{"key":"2026070905455657600_bib125","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/annonc\/mdy495","article-title":"Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic","volume":"30","author":"Chan","year":"2019","journal-title":"Ann Oncol"},{"key":"2026070905455657600_bib126","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13045-019-0770-1","article-title":"Cancer-associated fibroblasts: an emerging target of anti-cancer immunotherapy","volume":"12","author":"Liu","year":"2019","journal-title":"J Hematol Oncol"},{"key":"2026070905455657600_bib127","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41540-024-00419-4","article-title":"Spatial computational modelling illuminates the role of the tumour microenvironment for treating glioblastoma with immunotherapies","volume":"10","author":"Mongeon","year":"2024","journal-title":"NPJ Syst Biol Appl"},{"key":"2026070905455657600_bib128","doi-asserted-by":"crossref","first-page":"20170320","DOI":"10.1098\/rsif.2017.0320","article-title":"A computational multiscale agent-based model for simulating spatio-temporal tumour immune response to PD1 and PDL1 inhibition","volume":"14","author":"Gong","year":"2017","journal-title":"J R Soc Interface"},{"key":"2026070905455657600_bib129","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1010254","article-title":"Simulations of tumor growth and response to immunotherapy by coupling a spatial agent-based model with a whole-patient quantitative systems pharmacology model","volume":"18","author":"Ruiz-Martinez","year":"2022","journal-title":"PLoS Comput Biol"},{"key":"2026070905455657600_bib130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/CCI.18.00069","article-title":"A review of cell-based computational modeling in cancer biology","volume":"3","author":"Metzcar","year":"2019","journal-title":"JCO Clin Cancer Inform"},{"key":"2026070905455657600_bib131","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.semcancer.2011.04.001","article-title":"Analysis of cancer signaling networks by systems biology to develop therapies","volume":"21","author":"Prasasya","year":"2011","journal-title":"Semin Cancer Biol"}],"container-title":["Endocrine-Related Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/erc.bioscientifica.com\/view\/journals\/erc\/32\/8\/ERC-25-0067.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/erc.bioscientifica.com\/downloadpdf\/journals\/erc\/32\/8\/ERC-25-0067.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article-pdf\/doi\/10.1530\/ERC-25-0067\/145334\/erc-25-0067.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article-pdf\/doi\/10.1530\/ERC-25-0067\/145334\/erc-25-0067.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T09:46:22Z","timestamp":1783590382000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article\/32\/8\/e250067\/25978\/Systems-biology-successes-and-areas-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,1]]},"references-count":131,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8,1]]}},"URL":"https:\/\/doi.org\/10.1530\/erc-25-0067","relation":{},"ISSN":["1479-6821","1351-0088"],"issn-type":[{"value":"1479-6821","type":"electronic"},{"value":"1351-0088","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8,1]]},"article-number":"e250067"}}